| Literature DB >> 15273395 |
V Verez-Bencomo1, V Fernández-Santana, Eugenio Hardy, Maria E Toledo, Maria C Rodríguez, Lazaro Heynngnezz, Arlene Rodriguez, Alberto Baly, Luis Herrera, Mabel Izquierdo, Annette Villar, Yury Valdés, Karelia Cosme, Mercedes L Deler, Manuel Montane, Ernesto Garcia, Alexis Ramos, Aristides Aguilar, Ernesto Medina, Gilda Toraño, Iván Sosa, Ibis Hernandez, Raydel Martínez, Alexis Muzachio, Ania Carmenates, Lourdes Costa, Félix Cardoso, Concepción Campa, Manuel Diaz, René Roy.
Abstract
Glycoconjugate vaccines provide effective prophylaxis against bacterial infections. To date, however, no commercial vaccine has been available in which the key carbohydrate antigens are produced synthetically. We describe the large-scale synthesis, pharmaceutical development, and clinical evaluation of a conjugate vaccine composed of a synthetic capsular polysaccharide antigen of Haemophilus influenzae type b (Hib). The vaccine was evaluated in clinical trials in Cuba and showed long-term protective antibody titers that compared favorably to licensed products prepared with the Hib polysaccharide extracted from bacteria. This demonstrates that access to synthetic complex carbohydrate-based vaccines is feasible and provides a basis for further development of similar approaches for other human pathogens.Entities:
Mesh：
Substances：
Year: 2004 PMID： 15273395 DOI： 10.1126/science.1095209
Source DB: PubMed Journal: Science ISSN： 0036-8075 Impact factor: 47.728